Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Cazzola, A. Salzillo, P. Noschese, C. De Giglio, G. D‘Amato (Naples, Italy). Efficacy of a combination therapy with single inhaler budesonide/formoterol in the treatment of acute exacerbations of COPD (AECOPD). Eur Respir J 2004; 24: Suppl. 48, 1659

Member's Comments

No comment yet.

Related content which might interest you: COPD exacerbations are reduced by budesonide/formoterol in a single inhaler Source: Eur Respir J 2003; 22: Suppl. 45, 238s Year: 2003 A new budesonide/formoterol inhalation therapy in patients with asthma, COPD and ACOS Source: International Congress 2017 – Bronchial asthma management Year: 2017 The role of nebulised budesonide in the treatment of acute exacerbations of COPD Source: Eur Respir J 2007; 30: 399-400 Year: 2007 Comparison of oral prednisolone and nebulized budesonide in the treatment of acute exacerbations of COPD Source: Eur Respir J 2001; 18: Suppl. 33, 214s Year: 2001 Efficacy of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in COPD Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Improved and maintained asthma control with once-daily budesonide/formoterol single inhaler therapy in mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001 Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation-related antibiotic use in patients with COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Triple therapy of umeclidinium and inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) vs placebo + ICS/LABA in GOLD D patients Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Effects of add-on treatment with budesonide/formoterol combination in eosinophilic COPD patients Source: International Congress 2017 – Management of COPD Year: 2017 Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol Source: Eur Respir J 2004; 24: Suppl. 48, 291s Year: 2004 Utility of inhaled corticosteroids (fluticasone/formoterol) by pressurized metered-dose inhaler for the early management of acute exacerbations of asthma Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥1 exacerbation in the previous year: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Clinical efficacy of nebulised budesonide in acute exacerbation of COPD Source: Annual Congress 2010 - COPD: treatment and monitoring Year: 2010 Are COPD patients taking triple combination inhalers being overmedicated during acute exacerbations? Source: International Congress 2019 – COPD treatment: cohorts and real-world studies Year: 2019 Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004 The IMPACT of triple versus dual single-inhaler therapy on exacerbations of COPD Source: Breathe, 14 (4) 333; 10.1183/20734735.026418 Year: 2018 Impact of adherence to treatment with tiotropium co-administered with fluticasone propionate/salmeterol combination in COPD patients Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 Once-daily budesonide/formoterol via a single inhaler is effective in mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001 Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020